Details for Patent: 9,157,121
✉ Email this page to a colleague
Which drugs does patent 9,157,121 protect, and when does it expire?
Patent 9,157,121 protects FANAPT and is included in one NDA.
This patent has sixteen patent family members in seven countries.
Summary for Patent: 9,157,121
| Title: | Method of treatment based on polymorphisms of the KCNQ1 gene |
| Abstract: | The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation. |
| Inventor(s): | Wolfgang; Curt D. (Germantown, MD), Polymeropoulos; Mihael H. (Potomac, MD) |
| Assignee: | Vanda Pharmaceuticals, Inc. (Washington, DC) |
| Application Number: | 14/632,914 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,157,121 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,157,121
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-001 | May 6, 2009 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | ⤷ Sign Up | ||||
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-002 | May 6, 2009 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | ⤷ Sign Up | ||||
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-003 | May 6, 2009 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | ⤷ Sign Up | ||||
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-004 | May 6, 2009 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | ⤷ Sign Up | ||||
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-005 | May 6, 2009 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | ⤷ Sign Up | ||||
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-006 | May 6, 2009 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,157,121
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2757713 | ⤷ Sign Up | |||
| European Patent Office | 2417267 | ⤷ Sign Up | |||
| European Patent Office | 3023506 | ⤷ Sign Up | |||
| European Patent Office | 3354753 | ⤷ Sign Up | |||
| Spain | 2604102 | ⤷ Sign Up | |||
| Spain | 2673603 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
